{"id":"https://openalex.org/W2160899423","doi":"https://doi.org/10.1002/acr.22598","title":"Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis","display_name":"Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis","publication_year":2015,"publication_date":"2015-04-01","ids":{"openalex":"https://openalex.org/W2160899423","doi":"https://doi.org/10.1002/acr.22598","mag":"2160899423","pmid":"https://pubmed.ncbi.nlm.nih.gov/25832859","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5054840"},"language":"en","primary_location":{"id":"doi:10.1002/acr.22598","doi":"https://doi.org/10.1002/acr.22598","is_oa":true,"landing_page_url":"https://doi.org/10.1002/acr.22598","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr.22598","source":{"id":"https://openalex.org/S13698240","display_name":"Arthritis Care & Research","issn_l":"0893-7524","issn":["0893-7524","1529-0123","2151-464X","2151-4658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis Care & Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr.22598","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055790903","display_name":"Atsushi Ogata","orcid":"https://orcid.org/0000-0003-3944-3442","observed_orcids":["https://orcid.org/0000-0003-3944-3442"]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Atsushi Ogata","raw_affiliation_strings":["Osaka University, Osaka, Japan","Dr. Ogata has received honoraria (less than $10,000 each) from Pfizer, UCB Japan, GlaxoSmithKline, Ono, Takeda, Mitsubishi Tanabe, and Daiichi Sankyo, and (more than $10,000) from Chugai"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka University, Osaka, Japan","institution_ids":["https://openalex.org/I98285908"]},{"raw_affiliation_string":"Dr. Ogata has received honoraria (less than $10,000 each) from Pfizer, UCB Japan, GlaxoSmithKline, Ono, Takeda, Mitsubishi Tanabe, and Daiichi Sankyo, and (more than $10,000) from Chugai","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079071350","display_name":"Tatsuya Atsumi","orcid":"https://orcid.org/0000-0001-5657-962X","observed_orcids":["https://orcid.org/0000-0001-5657-962X"]},"institutions":[{"id":"https://openalex.org/I205349734","display_name":"Hokkaido University","ror":"https://ror.org/02e16g702","country_code":"JP","type":"education","lineage":["https://openalex.org/I205349734"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tatsuya Atsumi","raw_affiliation_strings":["Hokkaido University, Hokkaido, Japan","Dr. Atsumi has received honoraria (less than $10,000 each) from Ono, Nippon Boehringer Ingelheim, Abbott Japan, Kissei, Dainippon Sumitomo, CSL Behring, Kyowa Hakko Kirin, Merck Sharp & Dohme, and Novo Nordisk, and (more than $10,000 each) from Astellas, Actelion Japan, AbbVie, Eisai, Merck Sharp & Dohme, Asahi Kasei, Otsuka, Daiichi Sankyo, Mitsubishi Tanabe, Takeda, Chugai, Pfizer, Bristol-Myers Squibb, Shionogi, Taisho Toyama, and GlaxoSmithKline"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hokkaido University, Hokkaido, Japan","institution_ids":["https://openalex.org/I205349734"]},{"raw_affiliation_string":"Dr. Atsumi has received honoraria (less than $10,000 each) from Ono, Nippon Boehringer Ingelheim, Abbott Japan, Kissei, Dainippon Sumitomo, CSL Behring, Kyowa Hakko Kirin, Merck Sharp & Dohme, and Novo Nordisk, and (more than $10,000 each) from Astellas, Actelion Japan, AbbVie, Eisai, Merck Sharp & Dohme, Asahi Kasei, Otsuka, Daiichi Sankyo, Mitsubishi Tanabe, Takeda, Chugai, Pfizer, Bristol-Myers Squibb, Shionogi, Taisho Toyama, and GlaxoSmithKline","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112352526","display_name":"Takaaki Fukuda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105296287","display_name":"Kurume University","ror":"https://ror.org/057xtrt18","country_code":"JP","type":"education","lineage":["https://openalex.org/I105296287"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takaaki Fukuda","raw_affiliation_strings":["Kurume University School of Medicine, Fukuoka, Japan","Dr. Fukuda has received honoraria (less than $10,000 each) from Bristol-Myers Squibb, Janssen, AbbVie, Chugai, Takeda, Mitsubishi Tanabe, and Eisai"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kurume University School of Medicine, Fukuoka, Japan","institution_ids":["https://openalex.org/I105296287"]},{"raw_affiliation_string":"Dr. Fukuda has received honoraria (less than $10,000 each) from Bristol-Myers Squibb, Janssen, AbbVie, Chugai, Takeda, Mitsubishi Tanabe, and Eisai","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103472477","display_name":"Yasuhiko Hirabayashi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yasuhiko Hirabayashi","raw_affiliation_strings":["Hikarigaoka Spellman Hospital, Miyagi, Japan","Dr. Hirabayashi has received honoraria (less than $10,000 each) from Chugai, Takeda, Pfizer, Mitsubishi Tanabe, and Janssen"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hikarigaoka Spellman Hospital, Miyagi, Japan","institution_ids":[]},{"raw_affiliation_string":"Dr. Hirabayashi has received honoraria (less than $10,000 each) from Chugai, Takeda, Pfizer, Mitsubishi Tanabe, and Janssen","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108113496","display_name":"Masaaki Inaba","orcid":"https://orcid.org/0000-0002-9552-395X","observed_orcids":["https://orcid.org/0000-0002-9552-395X"]},"institutions":[{"id":"https://openalex.org/I317356780","display_name":"Osaka City University","ror":"https://ror.org/02skfsw40","country_code":"JP","type":"education","lineage":["https://openalex.org/I317356780","https://openalex.org/I4387152983"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masaaki Inaba","raw_affiliation_strings":["Osaka City University, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka City University, Osaka, Japan","institution_ids":["https://openalex.org/I317356780"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089659933","display_name":"Naoki Ishiguro","orcid":"https://orcid.org/0000-0003-2041-4035","observed_orcids":["https://orcid.org/0000-0003-2041-4035"]},"institutions":[{"id":"https://openalex.org/I60134161","display_name":"Nagoya University","ror":"https://ror.org/04chrp450","country_code":"JP","type":"education","lineage":["https://openalex.org/I60134161"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Naoki Ishiguro","raw_affiliation_strings":["Nagoya University, Aichi, Japan","Dr. Ishiguro has received honoraria (less than $10,000 each) from Eli Lilly Japan, Daiichi Sankyo, Otsuka, Taisho Toyama, Ono, Kaken, UCB Japan, Janssen, Novo Nordisk, Novartis, Bayer, GlaxoSmithKline, Merck Sharp & Dohme, Teijin, Santen, and Pfizer, and (more than $10,000 each) from Chugai, Eisai, AbbVie, Astellas, Takeda, Mitsubishi Tanabe, and Bristol-Myers Squibb"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nagoya University, Aichi, Japan","institution_ids":["https://openalex.org/I60134161"]},{"raw_affiliation_string":"Dr. Ishiguro has received honoraria (less than $10,000 each) from Eli Lilly Japan, Daiichi Sankyo, Otsuka, Taisho Toyama, Ono, Kaken, UCB Japan, Janssen, Novo Nordisk, Novartis, Bayer, GlaxoSmithKline, Merck Sharp & Dohme, Teijin, Santen, and Pfizer, and (more than $10,000 each) from Chugai, Eisai, AbbVie, Astellas, Takeda, Mitsubishi Tanabe, and Bristol-Myers Squibb","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112327664","display_name":"Motokazu Kai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210136148","display_name":"Mie Chuo Medical Center","ror":"https://ror.org/039kky066","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210136148","https://openalex.org/I4210137409"]},{"id":"https://openalex.org/I4210137409","display_name":"National Hospital Organization","ror":"https://ror.org/03ntccx93","country_code":"JP","type":"government","lineage":["https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Motokazu Kai","raw_affiliation_strings":["National Hospital Organization Mie Chuo Medical Center, Mie, Japan","Dr. Kai has received honoraria (less than $10,000 each) from Chugai, Eisai, Mitsubishi Tanabe, and Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Hospital Organization Mie Chuo Medical Center, Mie, Japan","institution_ids":["https://openalex.org/I4210136148","https://openalex.org/I4210137409"]},{"raw_affiliation_string":"Dr. Kai has received honoraria (less than $10,000 each) from Chugai, Eisai, Mitsubishi Tanabe, and Pfizer","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022635017","display_name":"Daisuke Kawabata","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I22299242","display_name":"Kyoto University","ror":"https://ror.org/02kpeqv85","country_code":"JP","type":"education","lineage":["https://openalex.org/I22299242"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Daisuke Kawabata","raw_affiliation_strings":["Kyoto University, Kyoto, Japan","Dr. Kawabata has received honoraria (less than $10,000) from Chugai"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kyoto University, Kyoto, Japan","institution_ids":["https://openalex.org/I22299242"]},{"raw_affiliation_string":"Dr. Kawabata has received honoraria (less than $10,000) from Chugai","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041725043","display_name":"Daihei Kida","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152596","display_name":"Nagoya Medical Center","ror":"https://ror.org/04ftw3n55","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210137409","https://openalex.org/I4210152596"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Daihei Kida","raw_affiliation_strings":["Nagoya Medical Centre, Aichi, Japan","Dr. Kida has received honoraria (less than $10,000 each) from Chugai, Bristol-Myers Squibb, Eli Lilly Japan, Asahi Kasei, Pfizer, and Eisai"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nagoya Medical Centre, Aichi, Japan","institution_ids":["https://openalex.org/I4210152596"]},{"raw_affiliation_string":"Dr. Kida has received honoraria (less than $10,000 each) from Chugai, Bristol-Myers Squibb, Eli Lilly Japan, Asahi Kasei, Pfizer, and Eisai","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013526431","display_name":"Hitoshi Kohsaka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125602781","display_name":"Tokyo Medical and Dental University","ror":"https://ror.org/051k3eh31","country_code":"JP","type":"education","lineage":["https://openalex.org/I125602781","https://openalex.org/I4400009020"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hitoshi Kohsaka","raw_affiliation_strings":["Tokyo Medical and Dental University, Tokyo, Japan","Dr. Kohsaka has received honoraria (less than $10,000 each) from Chugai, Bristol-Myers Squibb, UCB Japan, Astellas, Nippon Shinyaku, Actelion Japan, Abbott Japan/AbbVie, Pfizer, Kowa, Ono, Asahi Kasei, Japan Blood Products Organization, Mitsubishi Tanabe, Santen, and Teijin"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tokyo Medical and Dental University, Tokyo, Japan","institution_ids":["https://openalex.org/I125602781"]},{"raw_affiliation_string":"Dr. Kohsaka has received honoraria (less than $10,000 each) from Chugai, Bristol-Myers Squibb, UCB Japan, Astellas, Nippon Shinyaku, Actelion Japan, Abbott Japan/AbbVie, Pfizer, Kowa, Ono, Asahi Kasei, Japan Blood Products Organization, Mitsubishi Tanabe, Santen, and Teijin","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037094720","display_name":"Ryutaro Matsumura","orcid":"https://orcid.org/0000-0002-6644-243X","observed_orcids":["https://orcid.org/0000-0002-6644-243X"]},"institutions":[{"id":"https://openalex.org/I4210117126","display_name":"Chiba East Hospital","ror":"https://ror.org/026rga753","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210117126","https://openalex.org/I4210137409"]},{"id":"https://openalex.org/I4210137409","display_name":"National Hospital Organization","ror":"https://ror.org/03ntccx93","country_code":"JP","type":"government","lineage":["https://openalex.org/I4210137409"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ryutaro Matsumura","raw_affiliation_strings":["National Hospital Organization, Chiba-East National Hospital, Chiba, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Hospital Organization, Chiba-East National Hospital, Chiba, Japan","institution_ids":["https://openalex.org/I4210117126","https://openalex.org/I4210137409"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083901171","display_name":"Seiji Minota","orcid":"https://orcid.org/0000-0003-4084-6804","observed_orcids":["https://orcid.org/0000-0003-4084-6804"]},"institutions":[{"id":"https://openalex.org/I146500386","display_name":"Jichi Medical University","ror":"https://ror.org/010hz0g26","country_code":"JP","type":"education","lineage":["https://openalex.org/I146500386"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Seiji Minota","raw_affiliation_strings":["Jichi Medical University, Tochigi, Japan","Dr. Minota has received honoraria (less than $10,000 each) from Chugai, UCB Japan, Eisai, Takeda, Asahi Kasei, Santen, Mitsubishi Tanabe, Pfizer, Astellas, AstraZeneca, and Daiichi Sankyo, and receives license fees and royalties for Actemra"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jichi Medical University, Tochigi, Japan","institution_ids":["https://openalex.org/I146500386"]},{"raw_affiliation_string":"Dr. Minota has received honoraria (less than $10,000 each) from Chugai, UCB Japan, Eisai, Takeda, Asahi Kasei, Santen, Mitsubishi Tanabe, Pfizer, Astellas, AstraZeneca, and Daiichi Sankyo, and receives license fees and royalties for Actemra","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012348080","display_name":"Masaya Mukai","orcid":"https://orcid.org/0000-0002-4931-0910","observed_orcids":["https://orcid.org/0000-0002-4931-0910"]},"institutions":[{"id":"https://openalex.org/I4210147254","display_name":"Sapporo City General Hospital","ror":"https://ror.org/0498kr054","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210147254"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masaya Mukai","raw_affiliation_strings":["Sapporo City General Hospital, Hokkaido, Japan","Dr. Mukai has received honoraria (less than $10,000 each) from Pfizer, Mitsubishi Tanabe, Janssen, AbbVie, Eisai, Novartis, and Chugai"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sapporo City General Hospital, Hokkaido, Japan","institution_ids":["https://openalex.org/I4210147254"]},{"raw_affiliation_string":"Dr. Mukai has received honoraria (less than $10,000 each) from Pfizer, Mitsubishi Tanabe, Janssen, AbbVie, Eisai, Novartis, and Chugai","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106082905","display_name":"Takayuki Sumida","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I146399215","display_name":"University of Tsukuba","ror":"https://ror.org/02956yf07","country_code":"JP","type":"education","lineage":["https://openalex.org/I146399215"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takayuki Sumida","raw_affiliation_strings":["University of Tsukuba, Ibaraki, Japan","Dr. Sumida has received honoraria (less than $10,000) from Chugai"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Tsukuba, Ibaraki, Japan","institution_ids":["https://openalex.org/I146399215"]},{"raw_affiliation_string":"Dr. Sumida has received honoraria (less than $10,000) from Chugai","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100804520","display_name":"Kiyoshi Takasugi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128702","display_name":"Dogo Onsen Hospital","ror":"https://ror.org/031dgzs07","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210128702"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kiyoshi Takasugi","raw_affiliation_strings":["Dogo Spa Hospital, Ehime, Japan","Dr. Takasugi has received honoraria (less than $10,000 each) from Mitsubishi Tanabe, Santen, and Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dogo Spa Hospital, Ehime, Japan","institution_ids":["https://openalex.org/I4210128702"]},{"raw_affiliation_string":"Dr. Takasugi has received honoraria (less than $10,000 each) from Mitsubishi Tanabe, Santen, and Pfizer","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109095899","display_name":"Shigenori Tamaki","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shigenori Tamaki","raw_affiliation_strings":["Nagoya Rheumatology Clinic, Nagoya, Japan","Dr. Tamaki has received honoraria (less than $10,000 each) from Astellas, Bristol-Myers Squibb, Mitsubishi Tanabe, Takeda, Pfizer, AbbVie, Eisai, Chugai, Santen, Teijin, Taisho Toyama, and Eli Lilly Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nagoya Rheumatology Clinic, Nagoya, Japan","institution_ids":[]},{"raw_affiliation_string":"Dr. Tamaki has received honoraria (less than $10,000 each) from Astellas, Bristol-Myers Squibb, Mitsubishi Tanabe, Takeda, Pfizer, AbbVie, Eisai, Chugai, Santen, Teijin, Taisho Toyama, and Eli Lilly Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083314956","display_name":"Tsutomu Takeuchi","orcid":"https://orcid.org/0000-0003-1111-8218","observed_orcids":["https://orcid.org/0000-0003-1111-8218"]},"institutions":[{"id":"https://openalex.org/I203951103","display_name":"Keio University","ror":"https://ror.org/02kn6nx58","country_code":"JP","type":"education","lineage":["https://openalex.org/I203951103"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tsutomu Takeuchi","raw_affiliation_strings":["Keio University, Tokyo, Japan","Dr. Takeuchi has received honoraria (more than $10,000 each) from Astellas, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, Pfizer, Santen, Takeda, Teijin, AbbVie, Asahi Kasei, Taisho Toyama, SymBio, Janssen, AstraZeneca, Eli Lilly Japan, Novartis, and Asahi Kasei Medical"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Keio University, Tokyo, Japan","institution_ids":["https://openalex.org/I203951103"]},{"raw_affiliation_string":"Dr. Takeuchi has received honoraria (more than $10,000 each) from Astellas, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, Pfizer, Santen, Takeda, Teijin, AbbVie, Asahi Kasei, Taisho Toyama, SymBio, Janssen, AstraZeneca, Eli Lilly Japan, Novartis, and Asahi Kasei Medical","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101000035","display_name":"Atsuhisa Ueda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I89630735","display_name":"Yokohama City University","ror":"https://ror.org/0135d1r83","country_code":"JP","type":"education","lineage":["https://openalex.org/I89630735"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Atsuhisa Ueda","raw_affiliation_strings":["Yokohama City University, Kanagawa, Japan","Dr. Ueda has received honoraria (less than $10,000 each) from Chugai, Merck Sharp & Dohme, ViiV Healthcare, Torii, and AbbVie"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yokohama City University, Kanagawa, Japan","institution_ids":["https://openalex.org/I89630735"]},{"raw_affiliation_string":"Dr. Ueda has received honoraria (less than $10,000 each) from Chugai, Merck Sharp & Dohme, ViiV Healthcare, Torii, and AbbVie","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075284186","display_name":"Kazuhiko Yamamoto","orcid":"https://orcid.org/0000-0001-9037-3625","observed_orcids":["https://orcid.org/0000-0001-9037-3625","https://orcid.org/0000-0002-7555-6295"]},"institutions":[{"id":"https://openalex.org/I74801974","display_name":"The University of Tokyo","ror":"https://ror.org/057zh3y96","country_code":"JP","type":"education","lineage":["https://openalex.org/I74801974"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kazuhiko Yamamoto","raw_affiliation_strings":["University of Tokyo, Tokyo, Japan","Dr. Yamamoto has received honoraria (less than $10,000 each) from Astellas, AbbVie, Abbott Japan, Janssen, Asahi Kasei, Santen, Taisho Toyama, Ono, Daiichi Sankyo, Mitsubishi Tanabe, Nippon Shinyaku, Takeda, Johnson & Johnson, Sanofi, Hisamitsu, Dainippon Sumitomo, and Fujifilm, and (more than $10,000 each) from Chugai, Eisai, Pfizer, UCB Japan, and Bristol-Myers Squibb"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Tokyo, Tokyo, Japan","institution_ids":["https://openalex.org/I74801974"]},{"raw_affiliation_string":"Dr. Yamamoto has received honoraria (less than $10,000 each) from Astellas, AbbVie, Abbott Japan, Janssen, Asahi Kasei, Santen, Taisho Toyama, Ono, Daiichi Sankyo, Mitsubishi Tanabe, Nippon Shinyaku, Takeda, Johnson & Johnson, Sanofi, Hisamitsu, Dainippon Sumitomo, and Fujifilm, and (more than $10,000 each) from Chugai, Eisai, Pfizer, UCB Japan, and Bristol-Myers Squibb","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063192431","display_name":"Hisashi Yamanaka","orcid":"https://orcid.org/0000-0001-8453-6731","observed_orcids":["https://orcid.org/0000-0001-8453-6731"]},"institutions":[{"id":"https://openalex.org/I4210136522","display_name":"Tokyo Women's Medical University","ror":"https://ror.org/03kjjhe36","country_code":"JP","type":"education","lineage":["https://openalex.org/I4210136522"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hisashi Yamanaka","raw_affiliation_strings":["Tokyo Women's Medical University, Tokyo, Japan","Dr. Yamanaka has received honoraria (less than $10,000 each) from Bristol-Myers Squibb, AbbVie, Daiichi Sankyo, Nippon Kayaku, Mitsubishi Tanabe, Pfizer, Takeda, and UCB Japan, and (more than $10,000 each) from Teijin, Chugai, and Astellas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tokyo Women's Medical University, Tokyo, Japan","institution_ids":["https://openalex.org/I4210136522"]},{"raw_affiliation_string":"Dr. Yamanaka has received honoraria (less than $10,000 each) from Bristol-Myers Squibb, AbbVie, Daiichi Sankyo, Nippon Kayaku, Mitsubishi Tanabe, Pfizer, Takeda, and UCB Japan, and (more than $10,000 each) from Teijin, Chugai, and Astellas","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048119101","display_name":"Hajime Yoshifuji","orcid":"https://orcid.org/0000-0001-7082-4900","observed_orcids":["https://orcid.org/0000-0001-7082-4900"]},"institutions":[{"id":"https://openalex.org/I22299242","display_name":"Kyoto University","ror":"https://ror.org/02kpeqv85","country_code":"JP","type":"education","lineage":["https://openalex.org/I22299242"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hajime Yoshifuji","raw_affiliation_strings":["Kyoto University, Kyoto, Japan","Dr. Yoshifuji has received honoraria (less than $10,000 each) from Mitsubishi Tanabe, Takeda, Pfizer, Chugai, Astellas, and Eisai"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kyoto University, Kyoto, Japan","institution_ids":["https://openalex.org/I22299242"]},{"raw_affiliation_string":"Dr. Yoshifuji has received honoraria (less than $10,000 each) from Mitsubishi Tanabe, Takeda, Pfizer, Chugai, Astellas, and Eisai","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103429551","display_name":"Akira Nomura","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akira Nomura","raw_affiliation_strings":["Chugai Pharmaceutical, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chugai Pharmaceutical, Tokyo, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"last","author":{"id":null,"display_name":"the Musashi Study Investigators","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"the Musashi Study Investigators","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":20,"corresponding_author_ids":["https://openalex.org/A5055790903"],"corresponding_institution_ids":["https://openalex.org/I98285908"],"apc_list":{"value":4640,"currency":"USD","value_usd":4640},"apc_paid":{"value":4640,"currency":"USD","value_usd":4640},"fwci":3.4633,"has_fulltext":true,"cited_by_count":32,"citation_normalized_percentile":{"value":0.92262154,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"67","issue":"10","first_page":"1354","last_page":"1362"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tocilizumab","display_name":"tocilizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.8939999938011169},{"id":"https://openalex.org/keywords/subcutaneous-tocilizumab","display_name":"subcutaneous tocilizumab","score":0.8899999856948853},{"id":"https://openalex.org/keywords/intravenous-tocilizumab","display_name":"intravenous tocilizumab","score":0.9760000109672546},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.6309999823570251},{"id":"https://openalex.org/keywords/disease-activity","display_name":"disease activity","score":0.4569999873638153},{"id":"https://openalex.org/keywords/clinical-remission","display_name":"clinical remission","score":0.9010000228881836},{"id":"https://openalex.org/keywords/serum-drug-levels","display_name":"serum drug concentration","score":0.8600000143051147},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.765999972820282},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.8429999947547913},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.45500001311302185},{"id":"https://openalex.org/keywords/drug-efficacy","display_name":"drug efficacy","score":0.4059999883174896}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9605892896652222},{"id":"https://openalex.org/C2777178219","wikidata":"https://www.wikidata.org/wiki/Q425154","display_name":"Tocilizumab","level":3,"score":0.9415643215179443},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.743233323097229},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6157451272010803},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5723609924316406},{"id":"https://openalex.org/C2778143017","wikidata":"https://www.wikidata.org/wiki/Q111208","display_name":"Erythrocyte sedimentation rate","level":2,"score":0.5719692707061768},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.4495505094528198},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44833287596702576},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3454284369945526}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007275","descriptor_name":"Injections, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010147","descriptor_name":"Pain Measurement","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016059","descriptor_name":"Range of Motion, Articular","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017060","descriptor_name":"Patient Satisfaction","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/acr.22598","doi":"https://doi.org/10.1002/acr.22598","is_oa":true,"landing_page_url":"https://doi.org/10.1002/acr.22598","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr.22598","source":{"id":"https://openalex.org/S13698240","display_name":"Arthritis Care & Research","issn_l":"0893-7524","issn":["0893-7524","1529-0123","2151-464X","2151-4658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis Care & Research","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5054840","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5054840","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis Care Res (Hoboken)","raw_type":"Text"},{"id":"pmid:25832859","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25832859","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis care & research","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":{"id":"doi:10.1002/acr.22598","doi":"https://doi.org/10.1002/acr.22598","is_oa":true,"landing_page_url":"https://doi.org/10.1002/acr.22598","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr.22598","source":{"id":"https://openalex.org/S13698240","display_name":"Arthritis Care & Research","issn_l":"0893-7524","issn":["0893-7524","1529-0123","2151-464X","2151-4658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis Care & Research","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320316454","display_name":"University of Occupational and Environmental Health","ror":"https://ror.org/020p3h829"},{"id":"https://openalex.org/F4320323453","display_name":"Hyogo College of Medicine","ror":"https://ror.org/001yc7927"},{"id":"https://openalex.org/F4320333003","display_name":"Chugai Pharmaceutical","ror":"https://ror.org/01vepzj85"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2160899423.pdf","grobid_xml":"https://content.openalex.org/works/W2160899423.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W1608734376","https://openalex.org/W1838548883","https://openalex.org/W1973007229","https://openalex.org/W1991229597","https://openalex.org/W2009481513","https://openalex.org/W2023761225","https://openalex.org/W2033299724","https://openalex.org/W2054059257","https://openalex.org/W2063485775","https://openalex.org/W2069473482","https://openalex.org/W2090069133","https://openalex.org/W2096862304","https://openalex.org/W2113398090","https://openalex.org/W2114308202","https://openalex.org/W2119046820","https://openalex.org/W2126049604","https://openalex.org/W2139339400","https://openalex.org/W2150952126","https://openalex.org/W2187675918","https://openalex.org/W2272291172","https://openalex.org/W2327897261"],"related_works":["https://openalex.org/W2271166227","https://openalex.org/W2908570927","https://openalex.org/W2755990244","https://openalex.org/W4416974625","https://openalex.org/W2911075975","https://openalex.org/W2163480494","https://openalex.org/W2889677414","https://openalex.org/W4250568463","https://openalex.org/W2322398788","https://openalex.org/W1608734376"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"evaluate":[2],"the":[3,42,46,66,90,115,159,190],"efficacy":[4,269],"and":[5,102,130,141,149,225],"safety":[6,218,266],"of":[7,30,45,65,87,125,133,147,152,164,167,204,212],"switching":[8,245,274],"from":[9,96,201,246],"intravenous":[10],"(IV)":[11],"tocilizumab":[12],"(TCZ)":[13],"to":[14,68,98,209,251,262],"subcutaneous":[15],"(SC)":[16],"TCZ":[17,128,136,160,184,196,223,226,235],"monotherapy":[18,40],"in":[19,41,51,111,222,234,242,275],"rheumatoid":[20],"arthritis":[21],"patients.":[22],"METHODS:":[23],"Patients":[24,257],"who":[25,169],"had":[26,170],"completed":[27],"24":[28,175,208],"weeks":[29,77],"TCZ-SC":[31,59,88,99,105,252,263],"(162":[32,60,253],"mg/2":[33,61,254],"weeks)":[34,39,62,250,255],"or":[35],"TCZ-IV":[36,97,247,259],"(8":[37,248],"mg/kg/4":[38,249],"double-blind":[43],"period":[44],"MUSASHI":[47],"study":[48],"were":[49,71,122,142,220],"enrolled":[50],"an":[52],"84-week":[53],"open-label":[54,91],"extension":[55,92],"period.":[56],"All":[57],"received":[58,84],"monotherapy.":[63,256],"Effects":[64],"IV":[67],"SC":[69],"switch":[70,261],"evaluated":[72],"at":[73,138,144,155,173,180,206,214],"week":[74,139,156,174,181,207,215],"36":[75],"(12":[76],"after":[78,273],"switching).":[79],"RESULTS:":[80],"Overall,":[81],"319":[82],"patients":[83,165,186,244,277],"\u22651":[85],"dose":[86],"during":[89],"period;":[93],"160":[94],"switched":[95],"(TCZ":[100,106],"IV/SC)":[101],"159":[103],"continued":[104],"SC/SC).":[107],"Disease":[108],"Activity":[109],"Score":[110],"28":[112],"joints":[113],"using":[114],"erythrocyte":[116],"sedimentation":[117],"rate":[118],"clinical":[119],"remission":[120,172,179],"rates":[121],"62.5%":[123,145],"(100":[124,146],"160)":[126,148],"for":[127,135,229],"IV/SC":[129,161,185,224],"50.0%":[131],"(79":[132],"158)":[134],"SC/SC":[137,227],"24,":[140],"maintained":[143,241],"57.0%":[150],"(90":[151],"158),":[153],"respectively,":[154],"36.":[157,182,216],"In":[158,183],"group,":[162],"9%":[163],"(9":[166],"100)":[168],"achieved":[171],"could":[176],"not":[177],"maintain":[178],"weighing":[187],"\u226570":[188],"kg,":[189],"percentage":[191],"with":[192,278],"a":[193],"sufficient":[194],"serum":[195],"concentration":[197],"(\u22651":[198],"\u03bcg/ml)":[199],"decreased":[200],"90.9%":[202],"(10":[203],"11)":[205,213],"45.5%":[210],"(5":[211],"Overall":[217],"profiles":[219],"similar":[221],"except":[228],"mild":[230],"injection":[231],"site":[232],"reactions":[233],"IV/SC.":[236],"CONCLUSION:":[237],"Efficacy":[238],"is":[239],"adequately":[240],"most":[243],"receiving":[258],"can":[260],"without":[264],"serious":[265],"concerns.":[267],"Clinical":[268],"may":[270],"be":[271],"reduced":[272],"some":[276],"high":[279],"body":[280],"weight.":[281]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2016-06-24T00:00:00"}